Since 2003, Stallergenes has been carrying out the Oralair programme which addresses these unmet medical needs with EBM-documented, registered allergen tablets that are safe and easy-to-use.
This programme consists in the development of the four main allergens accounting for more than 80% of the epidemiology of these allergies: grass pollens, house dust mites, birch pollen and ragweed pollen.
The entire programme is in the clinical development stage and is proceeding according to schedule.
About Oralair(R) Grasses
With a safe and easy-to-use daily dose of Oralair(R) Grasses, patients enjoy a very significant alleviation of all their rhino-conjunctivitis symptoms, a marked reduction in their symptomatic medication use and a noticeable improvement in their quality of life.
Oralair(R) Grasses is a fast-dissolving tablet that has demonstrated
high efficacy in allergic rhino-conjunctivitis to grass pollen in the first
season, throughout the pollen season and at the pollen peak on:
- poly- and mono-sensitised patients, as well as asthmatic patients,
- every individual symptom, and in peculiar in nasal congestion and
Oralair(R) Grasses is a pre-coseasonal treatment: it has to be started four months before the pollen season, maintained throughout the season, then stopped and restarted the following season.
Oralair(R) Grasses contains a mix of 5 standardised grass allergens: perennial rye grass (Lolium perenne), meadow grass (Poa pratensis), timothy grass (Phleum pratense), cocksfoot (Dactylis glomerata) and sweet vernal grass (Anthoxanthum odoratum), as a daily dose of 300 IR, so as to mimic patients' natural exposure.
The clinical development programme has already enrolled around 1600
Copyright©2008 PR Newswire.
All rights reserved